Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESLIM-02: sovleplenib in warm autoimmune hemolytic anemia
CTR20221854Phase 3Completed
- Sponsor
- HUTCHMED
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sovleplenib in warm autoimmune hemolytic anemia (wAIHA), sponsored by HUTCHMED. Started Sep 2022; status: completed.
02
Drugs
sovleplenib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on CTR20221854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221854.